A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
News|Articles|August 3, 2026
This Month in Derm: July 2026 Podcasts
Author(s)Marie Bosslett, Assistant Editor
This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.
Advertisement
Advertisement
From topical steroid withdrawal and pediatric psychodermatology to skin of color representation and newborn skin barrier development, this month’s dermatology podcasts highlighted how rapidly the specialty is evolving beyond traditional clinical boundaries. Across conversations, experts emphasized a common theme: improving patient outcomes increasingly depends on understanding dermatologic disease within a broader biologic, psychosocial, and multidisciplinary context.
Related to this article
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
Dermatology Times is looking back on the top stories in dermatology from the month of October.
Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.
Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.
Advertisement
Advertisement